Innosuisse supports Surgical Fusion Technologies with 1.2 million Swiss francs

(CONNECT) The Swiss Innovation Agency Innosuisse is supporting Surgical Fusion Technologies GmbH with a grant of 1.2 million Swiss francs. According to a statement from the medtech company based in the Bio-Technopark Schlieren-Zurich, this will accelerate the development of next-generation solutions for soft tissue bone fixation. These are intended to improve surgical results in sports medicine and orthopaedic procedures.

The name of the project is Aligned Fibers for Ultrasonically Bioactivated Implants (AFUBI). It involves as project partners both the Institute for Materials Engineering and Plastics Processing at the OST - Eastern Switzerland University of Applied Sciences, as well as the three institutes of the University of Applied Sciences and Arts Northwestern Switzerland for Polymer Nanotechnology, Polymer Technology and Chemistry & Bioanalytics.

The AFUBI project introduces a fixation concept based on ultrasound-activated, fully bioresorbable anchors that fuse directly with the cancellous bone during implantation. The controlled release of bioactive bioglass fibers via the company's own SupraFusion platform is intended to accelerate bone integration. By liquefying the implant surface locally using ultrasound, the technology enables micro-invasive anchoring with less bone trauma compared to current anchors.

"This extremely welcome grant from Innosuisse is an important endorsement of our technology and its potential to redefine how bioresorbable implants connect to bone," said Chief Technology Officer Jörg Mayer. "The AFUBI project enables us to further develop a minimally invasive fixation approach that combines mechanical performance with biologically active interfaces." ce/mm